John WestwickProfessor John Westwick
Professor of Pharmacology, Imperial College, London University
Formerly, Novartis Institutes for Biomedical Research (NIBR),1999-2012

Professor John Westwick has more than 13 years leading pharmaceutical R&D and over 25 years as a scientist in academia.

From April 1999 until December 2012 he was the Global Head of the Respiratory Diseases Area and VP for NIBR based in Horsham in the UK. He was responsible for the leadership of all aspects of drug discovery from target validations to completion of PoCs in the clinic, in the Respiratory Area for Novartis. During his period of leadership, Novartis had five global launches in Respiratory namely Xolair, TOBI podhaler, Onbrez, Seebri and Ultibro. In addition Respiratory had 14 positive PoCs, a number of which are now in late development, including QAW039, an oral CRTH2 antagonist, QAX576, an anti-IL-13 mab, and QGE031, a high affinity anti-IgE mab. Furthermore three new treatments for Cystic Fibrosis and two new chemokine antagonists for COPD are presently in PoC trials.

In 1990 John was appointed Professor of Pharmacology and headed the Department of Pharmacy and Pharmacology at the University of Bath from 1990 until 1999. In 1987 John was a co-discoverer of Interleukin-8, the grand-daddy of the chemokine superfamily. He has over 175 full papers and book chapters in the fields of Pharmacology and Immunology. He has visiting Professorships in the Department of Respiratory Medicine, Imperial College, London and Department of Pathology, University of Michigan, USA and is a consultant or SAB member to a number of global organizations. In 2013 he received the Sir James Black award for “Contributions to Drug Discovery” from the British Pharmacological Society.